Troy Edward Wilson - 13 Nov 2025 Form 4 Insider Report for Kura Oncology, Inc. (KURA)

Role: President and CEO, Director
Signature: Teresa Bair, Attorney-in-fact for Troy E. Wilson
Issuer symbol: KURA
Transactions as of: 13 Nov 2025
Net transactions value: $0
Form type: 4
Filing time: 14 Nov 2025, 20:00:10 UTC
Previous filing: 29 Sep 2025
Next filing: 06 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
WILSON TROY EDWARD	President and CEO, Director	C/O KURA ONCOLOGY, INC., 4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO	Teresa Bair, Attorney-in-fact for Troy E. Wilson	14 Nov 2025	0001589597

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KURA	Common Stock	Award	$0	+182,500	+74%	$0.000000	429,353	13 Nov 2025	Direct	F1
holding	KURA	Common Stock						279,194	13 Nov 2025	by One Fish Two Fish Revocable Trust
holding	KURA	Common Stock						300,000	13 Nov 2025	by Lorax Charitable Remainder Unitrust

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents 1/3rd of the underlying shares of performance-based restricted stock units ("PSUs") granted to the Reporting Person on May 31, 2023. Each PSU represents the contingent right to receive one share of the Issuer's common stock based on the achievement of each of three specified development milestones, and the one-year anniversary of each milestone achievement, subject to the Reporting Person's continuous service on each corresponding vesting date. The performance criteria for one specified development milestone was determined to be met on November 13, 2025, resulting in the vesting of 1/6th of the underlying shares.

Content

Represents 1/3rd of the underlying shares of performance-based restricted stock units ("PSUs") granted to the Reporting Person on May 31, 2023. Each PSU represents the contingent right to receive one share of the Issuer's common stock based on the achievement of each of three specified development milestones, and the one-year anniversary of each milestone achievement, subject to the Reporting Person's continuous service on each corresponding vesting date. The performance criteria for one specified development milestone was determined to be met on November 13, 2025, resulting in the vesting of 1/6th of the underlying shares.